<DOC>
	<DOCNO>NCT02355119</DOCNO>
	<brief_summary>Patients resect pancreatic cancer fulfill selection criterion randomize receive one two treatment arm period 6 month : Gemcitabine , standard arm , FOLFOXIRI ( combination 5-Fluorouracil/Folinic Acid , Oxaliplatin Irinotecan ) , experimental arm . A total 310 patient enrol 50 Italian center .</brief_summary>
	<brief_title>Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine Adjuvant Treatment Resected Pancreatic Cancer</brief_title>
	<detailed_description>Patients resect stage I-III pancreatic cancer fulfill selection criterion randomize receive one two treatment arm period 6 month : Gemcitabine , standard arm , FOLFOXIRI ( combination 5-Fluorouracil/Folinic Acid , Oxaliplatin Irinotecan ) , experimental arm . A total 310 patient enrol 50 Italian center . All patient follow treatment disease progression death minimum 60 month . Main objective : To show increase disease-free survival HR 0.70 patient enrol experimental arm compare standard arm . Secondary objective : To show increase overall survival HR 0.70 patient enrol experimental arm compare standard arm . To show tolerability experimental treatment set . Principal inclusion criterion : - histological diagnosis pancreatic cancer - surgical resection curative intent within 10 week enrollment ( stage I-III ) - absence evidence metastasis ( cM0 ) - age 18-75 - ECOG performance status 0-1 - adequate bone marrow , liver renal function - write informed consent Principal exclusion criterion : - evidence metastases - CA19.9 high 2.5 x ULN ( upper limit normal range ) - precedent chemotherapy radiotherapy - coexisting malignancy - relevant coexisting disease could contraindicate participation study - hypersensitivity/intolerance drug study - pregnancy breastfeed - neurotoxicity grade &gt; 1 - malabsorption syndrome Primary end-point : Disease-free survival , define time enrollment evidence progression disease death . Secondary end-points : Overall survival , define time enrollment evidence death . Toxicity , define accord NCI-CTC</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>histological diagnosis pancreatic cancer surgical resection curative intent within 10 week enrollment ( stage IIII ) absence evidence metastasis ( cM0 ) age 1875 ECOG performance status 01 adequate bone marrow , liver renal function write informed consent evidence metastasis CA19.9 high 2.5 x ULN ( upper limit normal range ) precedent chemotherapy radiotherapy coexist malignancy relevant coexisting disease could contraindicate participation study hypersensitivity/intolerance drug study pregnancy breastfeed neurotoxicity grade &gt; 1 malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>